Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients

Diabetes Technology and Therapeutics

Volumn 14, Issue 6, 2012, Pages 475-484

  Derosa, Giuseppe ^a   Ragonesi, Pietro D ^b   Carbone, Anna ^c   Fogari, Elena ^a   Bianchi, Lucio ^a   Bonaventura, Aldo ^a   Romano, Davide ^a   Cicero, Arrigo F G ^d   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c Hospital Center of Diabetes   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARGININE; C PEPTIDE; C REACTIVE PROTEIN; GLUCAGON; INSULIN; METFORMIN; PLACEBO; PROINSULIN; VILDAGLIPTIN;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROINSULIN FASTING PLASMA INSULIN RATIO; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADAMANTANE; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; WEIGHT LOSS;

EID: 84861982613     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0278     Document Type: Article

References (50)

1. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-1570. (Pubitemid 33639596)
2. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5¢-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-1455. (Pubitemid 36432086)
3. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide- 1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-4605. (Pubitemid 32055138)
4. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an Nterminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
5. Triplitt CL: New technologies and therapies in the management of diabetes. Am J Manag Care 2007;13:547-554.
6. Triplitt C, McGill JB, Porte D Jr, Conner CS: The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes. J Manag Care Pharm 2007;13:S2-S16.
7. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ‡75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011;13:55-64.
8. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS: Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-3604. (Pubitemid 37034501)
9. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF: Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-895.
10. Deeks ED, Scott LJ: Pioglitazone/metformin. Drugs 2006;66:1863-1877. (Pubitemid 44584007)
11. Derosa G, Putignano P, Bossi AC, Bonaventura A, Querci F, Franzetti IG, Guazzini B, Testori G, Fogari E, Maffioli P: Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011;666:251-256.
12. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF: Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010;12:233-240.
13. Derosa G, Maffioli P: Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011;4:263-271.
14. Derosa G, Maffioli P: Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012;14:350-364.
15. Hundal RS, Inzucchi SE: Metformin: new understandings, new uses. Drugs 2003;63:1879-1894. (Pubitemid 37108399)
16. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD): Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136. (Pubitemid 46137814)
17. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J: Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-2191. (Pubitemid 44465710)
18. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-27. (Pubitemid 8302924)
19. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-730.
20. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-266.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
22. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495. (Pubitemid 38680001)
23. Houssa P, Dinensen B, Deberg M, Frank BH, Van Schravendijk C, Sodoyez-Goffaux F, Sodoyez J-C: First direct assay for intact human proinsulin. Clin Chem 1998;44:1514-1519. (Pubitemid 28309113)
24. El Kenz H, Bergmann P: Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur. Clin Lab 2004;50:171-174. (Pubitemid 38477541)
25. Holst JJ: Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-388.
26. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946. (Pubitemid 32756432)
27. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141.
28. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223. (Pubitemid 9249478)
29. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ: One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-768.
30. Fasching P, Ratheiser K, Nowotny P, Uurzemann S, Parker S, Waldhaus W: Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1994;43:385-389.
31. nded. New York: McGraw-Hill, 1971.
32. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE: Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:675-682. (Pubitemid 352044298)
33. Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA: Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010;42:663-669.
34. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-174. (Pubitemid 46206560)
35. Goodman M, Thurston H, Penman J: Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368-373.
36. Bolli G, Dotta F, Rochotte E, Cohen SE: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90. (Pubitemid 350302434)
37. Bosi E, Dotta F, Jia Y, Goodman M: Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-515.
38. Foley JE, Jordan J: Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010;6:541-548.
39. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25- year follow-up study. Lancet 1992;340:925-929.
40. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794. (Pubitemid 29536364)
41. American Diabetes Association: Summary of revisions to the 2011 clinical practice recommendations. Diabetes Care 2011;34(Suppl 1):S3.
42. Derosa G, Maffioli P: Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther 2010;12:491-501.
43. Derosa G, Tinelli C, Maffioli P: Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009;11:1091-1099.
44. Derosa G: Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-1961.
45. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-4894. (Pubitemid 41159387)
46. He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE: Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633-641. (Pubitemid 46632151)
47. D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE: Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009;94:81-88.
48. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte Jr D: Diminished B cell secretory capacity in patients with non-insulin- dependent diabetes mellitus. J Clin Invest 1984;74: 1318-1328. (Pubitemid 15206828)
49. Foley JE, Bunck MC, Möller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ, Diamant M: Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011;54:1985-1991.
50. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE: Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-1243.